Literature DB >> 25793032

Case report: isolated cardiac amyloidosis: an enigma unravelled.

Umair Khalid1, Omar Awar1, Gordana Verstovsek1, Benjamin Cheong2, Sarvari Venkata Yellapragada3, Hani Jneid3, Anita Deswal3, Salim S Virani3.   

Abstract

Amyloidosis is a rare, multisystem disease characterized by deposition of fibrils in extracellular tissue involving kidney, liver, heart, autonomic nervous system, and several other organs. This report discusses a 75-year-old male who presented with worsening dyspnea on exertion, orthopnea, and lower-extremity edema. On physical exam, he had elevated jugular venous pressure and lower-extremity edema. Electrocardiogram depicted low voltage in limb leads and a prolonged PR interval. Echocardiogram revealed left ventricular hypertrophy, severe biatrial dilatation, and restrictive filling physiology. Coronary angiography showed absence of significant epicardial coronary artery disease. On right heart catheterization, a "dip-and-plateau sign" was noted on right ventricular pressure tracings. A diagnosis of cardiac amyloidosis was considered, but a complete hematology work-up for systemic amyloidosis was negative. Cardiac magnetic resonance imaging was pursued, showing delayed gadolinium enhancement, and this ultimately led to the myocardial biopsy confirming the diagnosis of isolated cardiac amyloidosis. Further genetic analyses confirmed isolated cardiac amyloid caused by mutant transthyretin protein (Val-122-Ile). Isolated cardiac amyloidosis is an extremely rare entity, and diagnosis may be difficult despite the use of multimodality imaging. If the index of suspicion is high, then myocardial biopsy should be considered.

Entities:  

Keywords:  amyloidosis; restrictive cardiomyopathy; transthyretin-related amyloid fibril protein

Mesh:

Year:  2015        PMID: 25793032      PMCID: PMC4362068          DOI: 10.14797/mdcj-11-1-53

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  16 in total

1.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.

Authors:  Leslie T Cooper; Kenneth L Baughman; Arthur M Feldman; Andrea Frustaci; Mariell Jessup; Uwe Kuhl; Glenn N Levine; Jagat Narula; Randall C Starling; Jeffrey Towbin; Renu Virmani
Journal:  Circulation       Date:  2007-10-24       Impact factor: 29.690

2.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

Authors:  D R Jacobson; R D Pastore; R Yaghoubian; I Kane; G Gallo; F S Buck; J N Buxbaum
Journal:  N Engl J Med       Date:  1997-02-13       Impact factor: 91.245

3.  Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies.

Authors:  Joel Buxbaum; Alice Alexander; James Koziol; Clement Tagoe; Ervin Fox; Dalane Kitzman
Journal:  Am Heart J       Date:  2010-05       Impact factor: 4.749

Review 4.  Infiltrative cardiovascular diseases: cardiomyopathies that look alike.

Authors:  James B Seward; Grace Casaclang-Verzosa
Journal:  J Am Coll Cardiol       Date:  2010-04-27       Impact factor: 24.094

5.  A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology.

Authors:  D R Jacobson; P D Gorevic; J N Buxbaum
Journal:  Am J Hum Genet       Date:  1990-07       Impact factor: 11.025

Review 6.  Evaluation and management of the cardiac amyloidosis.

Authors:  Joseph B Selvanayagam; Philip N Hawkins; Biju Paul; Saul G Myerson; Stefan Neubauer
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

7.  Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

Authors:  Claudio Rapezzi; Giampaolo Merlini; Candida C Quarta; Letizia Riva; Simone Longhi; Ornella Leone; Fabrizio Salvi; Paolo Ciliberti; Francesca Pastorelli; Elena Biagini; Fabio Coccolo; Robin M T Cooke; Letizia Bacchi-Reggiani; Diego Sangiorgi; Alessandra Ferlini; Michele Cavo; Elena Zamagni; Maria Luisa Fonte; Giovanni Palladini; Francesco Salinaro; Francesco Musca; Laura Obici; Angelo Branzi; Stefano Perlini
Journal:  Circulation       Date:  2009-09-14       Impact factor: 29.690

8.  Noninvasive diagnosis of biopsy-proven cardiac amyloidosis.

Authors:  Joseph E Rahman; Emelie F Helou; Ramona Gelzer-Bell; Richard E Thompson; Chih Kuo; E Rene Rodriguez; Joshua M Hare; Kenneth L Baughman; Edward K Kasper
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

Review 9.  The molecular biology and clinical features of amyloid neuropathy.

Authors:  Merrill D Benson; John C Kincaid
Journal:  Muscle Nerve       Date:  2007-10       Impact factor: 3.217

Review 10.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

View more
  3 in total

1.  Cardiac Amyloidosis, An Infiltrative Heart Disease Presenting as Arrhythmia-A Case Report.

Authors:  B Magesh; Deepak Kadeli; Sunil Bohra; V Krishnaprasath; R Keshava
Journal:  J Clin Diagn Res       Date:  2017-04-01

2.  Noninvasive Diagnostic Modalities in an Isolated Case of Cardiac Amyloidosis.

Authors:  Jennaire Lewars; Hersh Wazir; Brandon Gordon; Uyi Faluyi; Yousry Girgis
Journal:  Cureus       Date:  2021-04-21

3.  Cardiac amyloidosis presenting with recurrent ischaemic strokes.

Authors:  Suleiman Suleiman; John Joseph Coughlan; David Moore
Journal:  BMJ Case Rep       Date:  2020-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.